Effects of ticagrelor tablets combined with aspirin on adverse reactions and incidence of thromboembolism in patients with acute myocardial infarction
Xue Mei
Lai Haiyan
Li Qian
Abstract：Objective To evaluate the clinical effects of ticagrelor tablets in combination with aspirin for the treatment of a-cute myocardial infarction(AMI).Methods From January 2022 to June 2023,70 AMI patients treated at our hospital were enrolled and randomly assigned to a control group(n=35)and a study group(n=35).The control group received aspirin plus clopidogrel,while the study group received aspirin plus ticagrelor.Clinical efficacy,coagulation function indices,myo-cardial enzyme spectrum parameters,and the incidence of adverse events were compared between the two groups.Results The study group demonstrated a significantly higher overall response rate compared with the control group(P<0.05).Post-treatment,the study group exhibited longer prothrombin time(PT)and activated partial thromboplastin time(APTT),and lower fibrinogen(FIB)levels than the control group(all P<0.05).Myocardial injury markers-including lac-tate dehydrogenase(LDH),creatine kinase-MB(CK-MB),and total creatine kinase(CK)-were significantly lower in the study group(P<0.05).Moreover,the incidence of adverse reactions in the study group was significantly lower than in the control group(P<0.05).Conclusion In AMI patients,ticagrelor combined with aspirin enhances therapeutic efficacy,op-timizes coagulation profiles and myocardial enzyme parameters,alleviates clinical symptoms,and reduces the risk of throm-boembolic events.
Keywords：Acute myocardial infarctionTicagrelorAspirinCoagulation functionThromboembolism
Publication Date：2024-11-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 81-84 )